NCT06962904 - CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 7, 2025

Primary Completion Date

July 15, 2027

Study Completion Date

July 15, 2027

Conditions

Rotavirus Infections

Interventions

BIOLOGICAL

3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)

CDC-9 IRV dissolving MNP for intradermal administration is comprised of a single human rotavirus strain for protection against rotavirus infection

BIOLOGICAL

7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)

CDC-9 IRV dissolving MNP for intradermal administration is comprised of a single human rotavirus strain for protection against rotavirus infection

OTHER

Placebo

Placebo MNP (containing sucrose, sorbitol, maltodextrin, methylcellulose, HEPES, sodium chloride, and calcium chloride) administered intradermally

Trial Locations (1)

RECRUITING

Emory Children's Center - Vaccine Research Clinic, Atlanta